Squalamine

Category	Hepatitis B Virus (HBV)
CAS	148717-90-2
Description	Squalamine is a naturally derived broad-spectrum antibiotic that is predominantly derived from the livers of dogfish and other shark species. Squalamine is undergoing trials for treatment of non-small cell lung cancer (stage I/IIA) as well as general phase I pharmacokinetic studies. In 2005, the Food and Drug Administration granted squalamine Fast Track status for approval for treatment of age-related macular degeneration. However, the Genaera Corporation, the company that has done the most work with squalamine, discontinued trials for its use in treating prostate cancer and wet age-related macular degeneration in 2007. The Squalamine project was acquired by Ohr Pharmaceutical from the now liquidated Genaera, with the prospect of continuing the development of this drug to treat wet age-related macular degeneration.

Quotation Now

Product Information

Synonyms	MSI 1256; MSI-1256; MSI1256
Molecular Weight	627.96
Molecular Formula	C34H65N3O5S
Canonical SMILES	CC(C)C(CCC(C)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)NCCCNCCCCN)C)O)C)OS(=O)(=O)O
InChI	InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
InChIKey	UIRKNQLZZXALBI-MSVGPLKSSA-N
Purity	≥98% (HPLC)
Density	1.13g/cm3
Solubility	In vitro: 10 mM in DMSO
Appearance	Light yellow to yellow (Solid)
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	976
Exact Mass	627.46449336
Index Of Refraction	1.548
In Vitro	Squalamine can strongly displace membrane-bound cationic proteins such as Rac1, a ρ-GTPase recruited to the inner leaflet of the eukaryotic cytoplasmic membrane for the actin remodeling necessary for endocytosis. At concentrations between 20 and 60 μg/mL, squalamine has been shown to inhibit a broad array of growth factor-induced, actin-dependent responses in endothelial cells, including cell migration, cell division, and vascular tube formation in a 3D matrix.
In Vivo	One time daily treatment with squalamine (15 or 30 mg/kg per d s.c.) was started beginning on day 1 or 2 after viral administration and continuing until day 8 or 9, respectively. Survival was monitored, and animals that remained alive by day 21 were considered cured.
PSA	142.29000
Target	Bacterial; HBV
XLogP3-AA	4.3